By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Mystic Pharmaceuticals’ Intranasal Technology Introduces Solutions In Drug Delivery
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Mystic Pharmaceuticals’ Intranasal Technology Introduces Solutions In Drug Delivery
Technology

Mystic Pharmaceuticals’ Intranasal Technology Introduces Solutions In Drug Delivery

HerinaAyot
HerinaAyot
Share
4 Min Read
SHARE

Delivery of drugs, biopharmaceuticals and vaccines via the nose offer many compelling advantages including reduced nausea and toxicity and rapid onset. Nasal delivery devices improve patient compliance compared with parenteral administration, by providing improved ease of use via either caregiver-based or self administration, as well as obviating the need for biohazardous disposal of needle sharps.

Delivery of drugs, biopharmaceuticals and vaccines via the nose offer many compelling advantages including reduced nausea and toxicity and rapid onset. Nasal delivery devices improve patient compliance compared with parenteral administration, by providing improved ease of use via either caregiver-based or self administration, as well as obviating the need for biohazardous disposal of needle sharps. Austin, Texas based Mystic Pharmaceuticals is an integrated specialty pharmaceutical company that combines large and small molecule pharmaceuticals, biologic agents and vaccines with their advanced proprietary drug delivery technologies to meet the expanding healthcare demands of the global population. Their ophthalmic, intranasal, otic, oral and lyophilized drug delivery technologies are designed to provide pharmaceutical and biologic products which are lower cost, non-invasive, and simplified self administration for enhanced compliance, safety and convenience.

The need for rapid manufacturing capacity for vaccines has recently emerged as a major consideration for US bio-defense preparedness policy. The life science industry players have taken notice of Mystic’s technology in this arena and the company has been invited to present at OneMedForum NY 2011.

In addition to their innovative, problem-solving intranasal drug delivery technology, Mystic is developing an eye drop device for the ophthalmic market that greatly reduces the problems associated with medication waste and the “wet face syndrome” with the current eye dropper method. Effective eye drop administration from a bottle is further complicated by the challenges of having to tip back the head, while positioning a very small bottle over the eye, while squeezing the bottle with the appropriate level of force. Mystic’s device seeks to alleviate these problems and essentially resolve the dilemma with their eye cup design which aids the user in exact positioning of the device and in holding the eyelid in the optimum position.

More Read

Features and Benefits of Patient Engagement Software
MakoPlasty Robotic Surgical Procedure for Knee Replacements
5 Bits of Actionable Info from AAOS 2014 for Your Ortho Department
Tips & Tricks for Faster Recovery with Technology
Roche’s Proposed Takeover of Illumina—Game On for Universal DNA Sequencing?

The Mystic team and Timothy Sullivan were recognized in 2008 by Medical Device & Diagnostic Industry Magazine as one of the top 100 notable people in the medical device industry for their accomplishments in drug delivery. Further, the company was featured in the April 2011 issue of OnDrugDelivery.com for their novel advances in drug delivery.

In late 2010, the company was awarded a non-taxable grant of approximately $245,000  under the Qualifying Therapeutic Discovery Project (QTDP) program included in the Patient Protection and Affordable Health Care Act of 2010. To be eligible for the QTDP program, projects must show reasonable potential to result in new therapies to treat areas of unmet medical need and prevent, detect, or treat chronic or acute disease and conditions.

 

TAGGED:intranasal drug deliverymedical technology
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

health tool
Home HealthTechnologyWellness

Healthy Tech: 5 Devices Designed to Improve Health

July 23, 2013

Remote Monitoring Is on the Rise

July 5, 2014

There’s More to HealthCare Than Doctors and Hospitals

July 28, 2013

Can “Portfolio Theory” Be Applied to NIH Funding Decisions?

May 18, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?